U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease.
from ALS patients, advocates and members of Congress. In recent weeks the agency received more than 1,300 written comments from the ALS community supporting the treatment.
The powder-based drug is a combination of two older ingredients: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine. Cambridge, Massachusetts-based Amylyx has patented the combination and says the chemicals work together to shield cells from premature death.Some ALS patients already take both drugs separately, sometimes paying $5,000 a month for the prescription component, according to physicians.
One outside group that analyzes the cost effectiveness of new treatments pegged the drug’s value at between between $9,100 and $30,700 per year. The Institute for Clinical and Economic Review also noted that many patients are expected to take Amylyx’s drug in combination with an older therapy, which costs over $170,000 per year.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Much-debated drug from Amylyx for Lou Gehrig’s disease wins FDA approvalA much-debated drug for Lou Gehrig’s disease won U.S. approval on Thursday from the Food and Drug Administration.
Lire la suite »
Despite Questionable Data, Drug for Lou Gehrig’s Disease Wins FDA ApprovalA much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Lire la suite »
New drug to treat ALS-Lou Gehrig's disease partially funded by Ice Bucket ChallengeDousing yourself or someone else in ice-cold water started on social media eight years ago. The ALS Association received $115 million in donations.
Lire la suite »
ALS drug wins FDA approval despite questionable data | amNewYorkA much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Lire la suite »
NIH to fund unproven ALS drugs under patient-backed lawThe U.S. government will soon spend $25 million to help patients access experimental drugs for the incurable illness known as Lou Gehrig's disease
Lire la suite »